NCT06093984View on ClinicalTrials.gov

Cumulative Live Birth Rates in Dual Ovarian Stimulation Versus Two Antagonist Stimulations in Poor Ovarian Responders

NANot yet recruitingINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2026

Conditions

Infertility

Interventions

PROCEDURE

duostim vs. two antagonist ovarian stimulations

Human menopausal gonadotropin (HMG) 300 IU/day with flexible antagonist protocol is used for ovarian stimulation, except in luteal phase stimulation of the duostim group. In the duostim group, all of the embryos are frozen. Fresh transfers are performed in the control group, frozen embryo transfers are performed in both control and duostim groups.

All Listed Sponsors

lead

Shanghai First Maternity and Infant Hospital

OTHER

NCT06093984 - Cumulative Live Birth Rates in Dual Ovarian Stimulation Versus Two Antagonist Stimulations in Poor Ovarian Responders | Biotech Hunter | Biotech Hunter